Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency
Edward Adomako, Biochemist and Molecular Biologist, shared on LinkedIn:
”Thrombotic Thrombocytopenic Purpura (TTP): A Rare but Life-Threatening Medical Emergency
In clinical laboratory medicine, some conditions demand rapid recognition and immediate intervention.
One of these is Thrombotic Thrombocytopenic Purpura (TTP), a rare disorder that can become fatal if not treated promptly.
TTP occurs when there is a severe deficiency of the enzyme ADAMTS13, which normally regulates von Willebrand factor in the blood.
When this enzyme is lacking, abnormal platelet clumping can occur in small blood vessels, leading to microvascular thrombosis.
Key laboratory and clinical features include:
- Severe thrombocytopenia (low platelet count)
- Microangiopathic hemolytic anemia with schistocytes on peripheral smear
- Elevated LDH and bilirubin
- Neurological symptoms such as confusion or seizures
- Possible renal impairment
Historically, clinicians described a ‘pentad’ of symptoms, but in many cases, the combination of thrombocytopenia and hemolytic anemia is enough to raise strong suspicion.
Why early diagnosis matters
Without treatment, mortality from TTP can be extremely high.c
Fortunately, modern therapies such as therapeutic plasma exchange, corticosteroids, and targeted therapies like caplacizumab have dramatically improved survival rates.
The role of the laboratory
Laboratory professionals play a critical role in identifying:
- Schistocytes on peripheral blood smear
- Evidence of hemolysis
- ADAMTS13 activity testing when available
Early laboratory detection can be the difference between rapid life-saving treatment and delayed care.
For healthcare professionals:
Maintaining a high index of suspicion when encountering unexplained thrombocytopenia and hemolytic anemia is crucial.
As laboratory and healthcare professionals, our vigilance helps ensure that rare but critical conditions like TTP are recognized and treated in time.”
Stay updated with Hemostasis Today.
-
Apr 29, 2026, 07:12Matteo Foschi: Is There a Benefit to Switching DOACs After Breakthrough Stroke?
-
Apr 29, 2026, 07:02Enrico Ferro: Stroke Risk in PFA vs Radiofrequency Ablation
-
Apr 29, 2026, 06:03Proud to Recognize 6 Early Career Investigators as the Recipients of the 2026 JTH Editors’ Awards – JTH
-
Apr 29, 2026, 05:55On Hemophilia Care Advances, Collaboration and Access in India at IHC X 2026 – Hemophilia Federation India
-
Apr 29, 2026, 05:46Rajendra Tapadia: Strengthening Last-Mile Hemophilia Care Through Structured Community Outreach
-
Apr 29, 2026, 05:37Masoabi Sefojane: Whose Realities Shape Global Priorities in Hemophilia Care?
-
Apr 29, 2026, 05:24Filippo Cademartiri: Mandatory Reading for Anyone Who Mistakes Expertise for Certainty
-
Apr 29, 2026, 02:52Fengqian Chen: Another Reality Check for the Factor XI Inhibitor Race – Novartis’ Abelacimab Setback
-
Apr 29, 2026, 02:18Arnaud Baldivia: Peri-Procedural Stroke – An Underestimated Emergency in the Operating Room and in the ICU